On this page
A companion diagnostic is a laboratory test that identifies patients likely to benefit from a specific drug. It is approved by the FDA together with that drug as a regulatory pair, meaning the test result must guide whether a patient receives the treatment. The test's clinical validity depends on the drug's proven efficacy in the identified patient population.
- A companion diagnostic identifies patients who will respond to a specific therapy and is required before that drug can be used, distinguishing it from optional or general screening tests.
- The FDA approves companion diagnostics and their paired drugs together because the test's accuracy depends on the drug's clinical performance in the biomarker-positive population.
- Clinical validation of a companion diagnostic typically uses samples from the pivotal trial that supported the drug's approval, ensuring the test predicts real-world treatment benefit.
- A negative companion diagnostic result does not always eliminate treatment options; it may indicate the test failed to detect a relevant alteration, the sample was inadequate, or evidence for a finding has not yet reached the regulatory label.
- Regulatory oversight protects patients by requiring companion diagnostics to demonstrate analytical validity, clinical validity, and clinical utility before marketing, reducing the risk of false results that could lead to unnecessary or delayed treatment.
A companion diagnostic is a test that identifies which patients will benefit from a specific drug. Unlike general screening tests or biomarker panels, a companion diagnostic has a defined relationship to one therapy: it predicts drug response in a particular patient population, and the FDA approves it together with that drug as a regulatory pair.
The pairing matters because the test's clinical validity depends on the drug's proven efficacy in the identified population. A test that correctly identifies HER2-positive breast cancer patients, for example, is only a companion diagnostic if it is paired with a drug proven effective in HER2-positive disease. Separate the test from the drug, and the clinical logic breaks. This article explains how companion diagnostics work in clinical practice, why regulators approve them as pairs, how they differ from other diagnostic tests, and why that regulatory oversight protects patients.
What a companion diagnostic actually is
A companion diagnostic is a test that identifies patients likely to benefit from a specific drug and is required before that drug can be used. The test result determines treatment eligibility: if the test is positive for the relevant biomarker, the patient may proceed to the drug; if negative, the patient does not receive it. This is distinct from a complementary diagnostic, which is recommended but not required.
The defining feature is the regulatory pairing. The FDA approves a companion diagnostic and its paired drug together, treating them as inseparable. Trastuzumab (Herceptin), approved for HER2-positive metastatic breast cancer with the HercepTest immunohistochemistry assay, established this model early. More recently, FoundationOne CDx, a tissue-based genomic test, became the first broad companion diagnostic for cancer care in 2017, followed by FoundationOne Liquid CDx, a blood-based version, in 2020.
The test answers a specific clinical question: Does this patient have the biomarker that predicts response to this drug? The answer is binary for regulatory purposes, though clinical interpretation may be more nuanced.
How a companion diagnostic works in clinical practice
The sequence is fixed: test first, treatment decision second. A patient's tumor or blood sample is collected and sent to a laboratory that performs the companion diagnostic assay. The test analyzes the sample for the specific biomarker or set of biomarkers linked to the drug. The laboratory reports the result, typically as positive, negative, or indeterminate.
If the result is positive, the patient's oncologist or treating physician can prescribe the paired drug. If negative, that particular drug is not indicated, and the physician considers other treatment options. The test result is the gatekeeper; treatment selection flows from it.
This sequence protects patients in two ways. First, it ensures that patients who are unlikely to respond do not receive a drug that will not help them and may cause harm. Second, it creates a clear clinical record linking the test result to the treatment decision, which is essential for monitoring outcomes and safety.
A negative result does not always mean no targeted options remain available. It may mean the test did not detect a relevant alteration, the sample was inadequate, or evidence connecting a finding to treatment has not yet reached the regulatory label. Patients and clinicians should interpret negative results in context.
Why companion diagnostics are approved as a pair with drugs
The regulatory pairing exists because the test's clinical validity depends entirely on the drug's efficacy in the identified population. A companion diagnostic does not stand alone as a general biomarker test; its value is defined by its ability to predict response to one specific therapy.
Consider the logic: if a test identifies patients with a particular biomarker, but the drug paired with that test does not work better in biomarker-positive patients than in the general population, the test has no clinical utility. It becomes a way to select patients for a treatment that does not actually benefit them. Conversely, if a drug works only in biomarker-positive patients but clinicians use it without testing, many patients will be treated unnecessarily.
The pairing ensures that regulators evaluate both the test and the drug in the context of each other. The drug's clinical trial must demonstrate efficacy in the biomarker-positive population, and the test must be shown to reliably identify that population. Neither can be approved without the other. This interdependence is why companion diagnostics cannot be separated from their paired drugs in regulatory terms: the test's clinical meaning exists only in relation to the drug's proven benefit.
The FDA approval process for companion diagnostics
The FDA's review of a companion diagnostic focuses on analytical and clinical validation of the test while assessing safety and effectiveness. Analytical validation confirms that the test accurately detects the biomarker it is designed to measure. Clinical validation confirms that the test result correlates with the presence or absence of the biomarker in actual patient samples. Clinical utility demonstrates that the test result predicts response to the paired drug.
For more prevalent biomarkers, the FDA recommends that clinical validation be performed using samples from the pivotal clinical trial that supports the drug's approval. This approach anchors the test's performance to the exact patient population in which the drug was proven effective.
When the assay used during the clinical trial differs from the final companion diagnostic assay, a bridging study is required. The purpose is to demonstrate that the clinical efficacy observed with the trial assay is maintained with the final diagnostic assay, confirming that the test will perform as expected in real-world use.
Companion diagnostics are considered high-risk in vitro diagnostic devices given the role they play in therapeutic decision-making and the complications they may introduce with respect to sensitivity and specificity. False positive results can lead to unnecessary therapeutic interventions and delays in appropriate care. This risk profile justifies rigorous FDA oversight before a test reaches patients.
How companion diagnostics differ from other diagnostic tests
Not every diagnostic test is a companion diagnostic. The distinction lies in the regulatory relationship to a specific therapy and the defined clinical context in which the test is used. Understanding these boundaries clarifies what companion diagnostics are and why they matter.
Companion diagnostics versus screening and prognostic tests
A screening test detects disease in asymptomatic people or identifies risk of disease. A prognostic test predicts the course of disease once diagnosed. A companion diagnostic does neither. It assumes disease is already present and identifies which patients will respond to a specific treatment.
Screening for BRCA1 or BRCA2 mutations in healthy women, for example, is not a companion diagnostic; it is a risk assessment tool. A test that predicts whether a patient's breast cancer will recur is prognostic but not a companion diagnostic. A test that identifies HER2 status to determine eligibility for trastuzumab is a companion diagnostic because it selects patients for a specific therapy based on predicted response.
The clinical purpose is different. Screening and prognostic tests inform general medical decision-making. A companion diagnostic narrows to a single question: Should this patient receive this drug?
Companion diagnostics versus general biomarker tests
A broad genomic panel may analyze hundreds of genes and report many alterations, but not every finding is an FDA-recognized companion diagnostic result. A detailed panel may report a mutation in a gene associated with a targeted therapy, but if that gene-drug pairing has not been approved together as a regulatory pair, the result is not a companion diagnostic.
The distinction is regulatory and clinical. A companion diagnostic has a defined relationship to a specific therapy, a defined specimen type, a defined testing method, and a defined interpretation threshold. A general biomarker test may report the same alteration but without that regulatory pairing and without the clinical validation specific to a drug.
This matters for patients and clinicians. A companion diagnostic result carries the weight of FDA review and approval; it is a cleared pathway to treatment. A general biomarker finding, even if clinically relevant, may suggest a treatment option that is not yet formally approved for that indication or that has not been validated in that patient population.
Why regulatory approval and quality standards matter
FDA oversight of companion diagnostics protects patients by ensuring the test actually predicts drug response and is performed reliably. Without regulatory approval, a laboratory could market a test claiming to identify patients who will benefit from a drug without any requirement to prove that claim or to demonstrate that the test is accurate.
Regulatory approval requires analytical validation, confirming the test detects the intended biomarker with high sensitivity and specificity. It requires clinical validation, confirming the biomarker is present in real patient samples at the expected frequency. It requires clinical utility, confirming the test result predicts response to the paired drug in actual clinical use.
These standards reduce the risk of false results. A false positive test, one that incorrectly identifies a patient as having the biomarker, can lead to unnecessary treatment, side effects, and delayed access to appropriate alternatives. A false negative test, one that fails to identify a patient who has the biomarker, can deny a patient access to a treatment that would help them. FDA approval and the quality standards it enforces are designed to minimize both risks.
The FDA has encouraged early collaboration between drug and diagnostic developers. In August 2014, the agency issued final guidance on companion diagnostics to help companies identify the need for companion diagnostics at an earlier stage in drug development and plan for co-development. In June 2023, the FDA announced a voluntary pilot program for certain oncology drug products used with in vitro diagnostic tests. These initiatives reflect the agency's recognition that better coordination between drug and diagnostic development leads to more reliable tests and safer treatment pathways.
Where companion diagnostics fit in treatment decisions
A companion diagnostic result is a data point in a broader clinical decision. It answers one question, whether a patient has the biomarker that predicts response to a specific drug, but clinical care involves many other considerations: the patient's overall health, other treatment options, side effect tolerance, prior treatments, and personal preferences.
For researchers and analysts, companion diagnostics represent an important shift in how cancer treatment is selected. Rather than treating all patients with a given cancer type the same way, precision medicine uses diagnostic information to match patients to drugs most likely to help them. Companion diagnostics are the operational tool that makes this matching possible.
Understanding companion diagnostics is essential for anyone involved in cancer research, clinical care, or health policy. They shape which patients receive which drugs, they influence clinical trial design, they affect health economics and access to treatment, and they are central to the regulatory framework governing targeted therapies. A companion diagnostic is not merely a test; it is a regulated clinical pathway that connects diagnosis to treatment.
Do this automatically
A laboratory performing companion diagnostic assays must process each patient sample through analytical validation, clinical interpretation, and reporting, a sequence that accumulates across hundreds or thousands of tests annually as more drugs enter the companion diagnostic approval pathway. This repetitive, high-volume testing workflow across multiple assays and patient populations can be systematized and accelerated through software automation. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
